Immediate Reaction to Propranolol: An Extremely Rare but Important Condition. A Case Report.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Lucía González-Bravo, María-José Sánchez-González, José Barbarroja-Escudero, Josefa Monjo-Paz, Dorotea Matas-Dominguez, Melchor Alvarez-Mon
{"title":"Immediate Reaction to Propranolol: An Extremely Rare but Important Condition. A Case Report.","authors":"Lucía González-Bravo, María-José Sánchez-González, José Barbarroja-Escudero, Josefa Monjo-Paz, Dorotea Matas-Dominguez, Melchor Alvarez-Mon","doi":"10.2174/1574886318666230417103423","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Beta-blockers involve a group of drugs widely used nowadays. Propranolol was the first beta-blocker available in the market. It is the most prescribed first-generation betablocker and is commonly used. Beta-blocker allergy is extremely unusual. Only an isolated case of an urticaria reaction to propranolol has been published in 1975.</p><p><strong>Case presentation: </strong>We present a 44-year-old man. In 2016, he was treated with a daily dose of 5 mg of propranolol prescribed for a diagnosis of essential tremor. On the third day of medical treatment, he experienced an episode of generalized urticaria directly related to the administration of propranolol. He continued with his habitual treatment and he had no other urticaria episodes. A drug provocation test was carried out with gradually increasing doses of the culprit drug. Thirty minutes after a total cumulative dose of 5 mg, the patient had several hives on the chest, abdominal region and arms. Two weeks later, a new drug provocation test was performed to bisoprolol as an alternative beta-blocker, with good tolerance.</p><p><strong>Conclusion: </strong>We describe a new case of urticaria secondary to propranolol, presenting as an immediate hypersensitivity reaction. Bisoprolol has been succesfully proved to be a safe option. Bisoprolol is a second-generation beta-blocker, it is available and commercialized worldwide, which makes it a good alternative.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"303-305"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574886318666230417103423","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Beta-blockers involve a group of drugs widely used nowadays. Propranolol was the first beta-blocker available in the market. It is the most prescribed first-generation betablocker and is commonly used. Beta-blocker allergy is extremely unusual. Only an isolated case of an urticaria reaction to propranolol has been published in 1975.

Case presentation: We present a 44-year-old man. In 2016, he was treated with a daily dose of 5 mg of propranolol prescribed for a diagnosis of essential tremor. On the third day of medical treatment, he experienced an episode of generalized urticaria directly related to the administration of propranolol. He continued with his habitual treatment and he had no other urticaria episodes. A drug provocation test was carried out with gradually increasing doses of the culprit drug. Thirty minutes after a total cumulative dose of 5 mg, the patient had several hives on the chest, abdominal region and arms. Two weeks later, a new drug provocation test was performed to bisoprolol as an alternative beta-blocker, with good tolerance.

Conclusion: We describe a new case of urticaria secondary to propranolol, presenting as an immediate hypersensitivity reaction. Bisoprolol has been succesfully proved to be a safe option. Bisoprolol is a second-generation beta-blocker, it is available and commercialized worldwide, which makes it a good alternative.

普萘洛尔即刻反应:普萘洛尔的即刻反应:一种极为罕见但重要的病症。病例报告。
简介β-受体阻滞剂是当今广泛使用的一类药物。普萘洛尔是市场上第一种β-受体阻滞剂。它是处方量最大的第一代受体阻滞剂,也是常用的受体阻滞剂。对β-受体阻滞剂过敏的情况极为罕见。1975 年仅发表过一例普萘洛尔引起的荨麻疹反应:我们接诊了一名 44 岁的男性患者。2016 年,他因诊断为本质性震颤而接受了每天 5 毫克普萘洛尔处方剂量的治疗。在接受治疗的第三天,他出现了与服用普萘洛尔直接相关的全身性荨麻疹。他继续接受惯常的治疗,没有再出现荨麻疹。医生用逐渐增加剂量的罪魁祸首药物对他进行了药物诱发试验。在累计服用 5 毫克药物 30 分钟后,患者的胸部、腹部和手臂出现了数个荨麻疹。两周后,患者使用比索洛尔作为替代β-受体阻滞剂进行了新的药物激发试验,耐受性良好:我们描述了一例继发于普萘洛尔的荨麻疹新病例,表现为即刻超敏反应。事实证明,比索洛尔是一种安全的选择。比索洛尔是第二代β-受体阻滞剂,在世界各地均可买到并已商业化,因此是一种很好的替代药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current drug safety
Current drug safety PHARMACOLOGY & PHARMACY-
CiteScore
2.10
自引率
0.00%
发文量
112
期刊介绍: Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信